Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials DOI
Simon C. Dyall, Ikbal Andrian Malau,

Kuan-Pin Su

и другие.

Current Opinion in Clinical Nutrition & Metabolic Care, Год журнала: 2024, Номер unknown

Опубликована: Сен. 24, 2024

This review examines evidence from recent clinical trials on the therapeutic potential of omega-3 polyunsaturated fatty acids (PUFAs) in major depressive disorder (MDD). We focus effects MDD with comorbidities, younger populations, and high-inflammation presentations. PubMed, Cochrane, Embase databases were systematically searched for studies published between May 2022 2024. The search was conducted randomized controlled using PUFAs participants a diagnosis depression.Higher doses eicosapentaenoic acid (EPA) (>1 g/day) improved measures depression, particularly elevated inflammation markers, comorbid cardiovascular diseases, late-life onset, children adolescent populations. Improvements symptoms associated increases PUFA-derived anti-inflammatory proresolving lipid mediators. As adjuvant treatments, have benefits mood, cognitive metabolic functions, kynurenine serotonin pathways, alterations corticolimbic functional connectivity. While suggests promise, high-dose EPA inflammatory subtypes, more research is needed to establish optimal dosing regimens, treatment duration, patient subgroups most likely benefit. Future should sex differences, long-term effects, synergies other treatments.

Язык: Английский

Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials DOI
Simon C. Dyall, Ikbal Andrian Malau,

Kuan-Pin Su

и другие.

Current Opinion in Clinical Nutrition & Metabolic Care, Год журнала: 2024, Номер unknown

Опубликована: Сен. 24, 2024

This review examines evidence from recent clinical trials on the therapeutic potential of omega-3 polyunsaturated fatty acids (PUFAs) in major depressive disorder (MDD). We focus effects MDD with comorbidities, younger populations, and high-inflammation presentations. PubMed, Cochrane, Embase databases were systematically searched for studies published between May 2022 2024. The search was conducted randomized controlled using PUFAs participants a diagnosis depression.Higher doses eicosapentaenoic acid (EPA) (>1 g/day) improved measures depression, particularly elevated inflammation markers, comorbid cardiovascular diseases, late-life onset, children adolescent populations. Improvements symptoms associated increases PUFA-derived anti-inflammatory proresolving lipid mediators. As adjuvant treatments, have benefits mood, cognitive metabolic functions, kynurenine serotonin pathways, alterations corticolimbic functional connectivity. While suggests promise, high-dose EPA inflammatory subtypes, more research is needed to establish optimal dosing regimens, treatment duration, patient subgroups most likely benefit. Future should sex differences, long-term effects, synergies other treatments.

Язык: Английский

Процитировано

1